A growing number of drug makers are turning to royalty deals instead of selling new shares, and XOMA Royalty aims to profit by buying pieces of many medicines across different stages of development. The appeal is a more spread-out set of bets, but the story hinges on a handful of current products holding up and on future drug trials and legal outcomes going the right way.Read more
Catalysts About XOMA Royalty XOMA Royalty builds and manages a diversified portfolio of biotechnology royalty and milestone interests across the drug development cycle. What are the underlying business or industry changes driving this perspective?Read more
Catalysts About XOMA Royalty XOMA Royalty aggregates biotechnology royalty and milestone interests across the drug development spectrum, aiming to build a diversified, cash generative portfolio funded largely by third party R&D spend. What are the underlying business or industry changes driving this perspective?Read more
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
